RxDoctor Payments DataLook up a doctor →

Bashab Banerji, MD

Internal Medicine · Las Vegas, NVNPI 1659379717

Payments from drug & device makers

$25,899in general payments, 2019–2025

Across 447 payments — averaging $57.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$12K
  • AstraZeneca$3K
  • Amgen$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Bayer$789
  • GSK$777
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$1,7007%
  • Speaking & faculty fees$9,00035%
  • Food & beverage$15,00958%
  • Education$1901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,899 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$311,327
Medicare patients
415
Services billed
3,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$119,099
FarxigaDapagliflozin Propanediol32$32,544
XareltoRivaroxaban27$31,179
OzempicSemaglutide19$31,026
JanuviaSitagliptin Phosphate17$27,890
Repatha SyringeEvolocumab24$26,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$26,111
Repatha SureclickEvolocumab30$24,737
JardianceEmpagliflozin13$21,404
TrulicityDulaglutide14$19,753
KerendiaFinerenone13$19,402
VascepaIcosapent Ethyl19$17,582
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$16,411
SynthroidLevothyroxine Sodium174$15,653
NexletolBempedoic Acid23$13,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$180$119,09977 claims
AstraZenecaFarxiga$2,726$32,54432 claims
GSKTrelegy Ellipta, Breo Ellipta$777$31,71536 claims
Johnson & JohnsonXarelto$125$31,17927 claims
Novo NordiskOzempic$603$31,02619 claims
MerckJanuvia$16$27,89017 claims
Boehringer IngelheimJardiance$216$21,40413 claims
Lilly USA, LLCTrulicity$162$19,75314 claims
BayerKerendia$789$19,40213 claims
AbbVieSynthroid$631$15,653174 claims
Esperion Therapeutics, Inc.Nexletol$293$13,78123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →